RESPONSE: Response to Seladelpar in Subjects With Primary Biliary Cholangitis (PBC) and an Inadequate Control to or an Intolerance to Ursodeoxycholic Acid (UDCA)
Clinical trial NCT04620733 · COMPLETED
Trial details
- NCT number
- NCT04620733
- Sponsor
- Gilead Sciences
- Status
- COMPLETED
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2021-04-21
- Primary completion
- 2023-08-11
- Enrollment
- 193
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.